Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes
Efficacy of Lactobacillus Paracasei LC19 on Newly Diagnosed Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jia Liu, MD
- Phone Number: 010-85231710
- Email: liujia0116@126.com
Study Contact Backup
- Name: Xiaoyu Ding, MD
- Phone Number: 010-85231711
- Email: dxycy0828@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100020
- Recruiting
- Beijing Chao-Yang Hospital, Capital Medical University
-
Contact:
- Jia Liu, MD
- Phone Number: liujia0116@126 010-8523161710
- Email: dxycy0828@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-65 years, both genders eligible
- Drug-naive patients with newly diagnosed type 2 diabetes
- Subjects with screening HbA1c ≥ 7.0% and ≤ 9.0%
- Subjects understand the nature, significance, potential benefits, inconvenience, and risks and procedure of the study, and voluntarily sign the informed consent form
Exclusion Criteria:
- Other types of diabetes except T2D: type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes, or secondary diabetes (such as acromegaly or Cushing's syndrome, etc.)
- Subjects with acute diabetic complications such as diabetic ketoacidosis or diabetic hyperosmolar coma in the past 6 months
- Subjects with history of hypoglycemia in the past 6 months
- Subjects with history of New York Heart Association class (NYHA) grade of heart function ≥ III or serious cardiovascular diseases (myocardial infarction, or with the history of cardiac interventional therapy or stent implantation, valve disease or valve repair, unstable angina, transient ischemic attack or stroke) within 6 months before the screening period
- Subjects with history of chronic active hepatitis and/or severe liver dysfunction, renal dysfunction, and thyroid dysfunction
- Subjects with a medical history of malignant tumor
- Subjects with history of gastrointestinal diseases that affect food digestion and absorption (such as severe diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, active gastrointestinal ulcers, acute cholecystitis, etc.) or with a history of intestinal resection or other gastrointestinal surgery (such as cholecystectomy) within one year before the screening period
- Subjects with history of surgery, or severe trauma in the past 6 months, or planning to undergo surgery during the study period
- Subjects suffering from severe infections, severe anemia, or neutropenia
- Subjects pregnant or in lactation, or those planning to become pregnant or impregnate during or within 3 months after the study period
- Subjects with history of receiving immunosuppressants, steroids, anti diarrheal drugs, antibiotics, lipid-lowering drugs, or other gastrointestinal motility medications within the past 3 months;
- Subjects using other medications that can affect blood glucose in the past 3 months
- Subjects with consumption of other probiotic or prebiotic products in the past 3 months before secreening
- Subjects with lactose intolerance, known or suspected allergy to probiotics used in experiments, history of drug allergies or allergic diseases
- Subjects with weight fluctuations ≥ 5kg in the past 3 months or planning to take medication to control weight during the study period
- Subjects with history of mental illness or epilepsy, or taking antidepressant medications
- Subjects with history of alcohol abuse (for men, alcohol consumption exceeding 40 grams per day and for women, exceeding 20 grams per day)
- Subjects have participated in any other clinical study in the past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lactobacillus paracasei LC19 supplementation
|
Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention.
This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
|
|
Placebo Comparator: Placebo probiotic milk powder
|
Orally administered placebo probiotic milk powder, in addition to lifestyle intervention.
The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA.
These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c change
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Changes in HbA1c from baseline at12 weeks during follow-up
|
From enrollment to the end of treatment at 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
fasting blood glucose change
Time Frame: From baseline at 4, 8, and 12 weeks during follow-up
|
Changes in fasting blood glucose from baseline at 4, 8, and 12 weeks during follow-up
|
From baseline at 4, 8, and 12 weeks during follow-up
|
|
Glycated albumin change
Time Frame: From baseline at 4 and 12 weeks during follow-up
|
Changes in glycated albumin from baseline at 4 and 12 weeks during follow-up
|
From baseline at 4 and 12 weeks during follow-up
|
|
Glycemic achieving rate
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Glycemic achieving rate with HbA1c<6.5% at 12-week follow-up
|
From enrollment to the end of treatment at 12 weeks
|
|
Glucose tolerance
Time Frame: From baseline at 4 and 12 weeks during follow-up
|
Changes in blood glucose levels (at 0, 30, 60, and 120 minutes during OGTT) from baseline at 4 and 12 weeks during follow-up
|
From baseline at 4 and 12 weeks during follow-up
|
|
Insulin change
Time Frame: From baseline at 4 and 12 weeks during follow-up
|
Changes in insulin levels (at 0, 30, 60, and 120 minutes during OGTT) from baseline at 4 and 12 weeks during follow-up
|
From baseline at 4 and 12 weeks during follow-up
|
|
Plasma GLP-1 change
Time Frame: From baseline at 4 and 12 weeks during follow-up
|
Changes in GLP-1 levels (at 0, 30, 60, and 120 minutes during OGTT) from baseline at 4 and 12 weeks during follow-up
|
From baseline at 4 and 12 weeks during follow-up
|
|
BMI change
Time Frame: From baseline at 4, 8, and 12 weeks during follow-up
|
Changes in BMI from baseline at 4, 8, and 12 weeks during follow-up
|
From baseline at 4, 8, and 12 weeks during follow-up
|
|
Alteration of fecal metabolites
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Fecal metabolites analysis from baseline to 12-week follow-up
|
From enrollment to the end of treatment at 12 weeks
|
|
Alteration of gut microbiome
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Fecal metagenomics sequencing from baseline to 12-week follow-up
|
From enrollment to the end of treatment at 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guang Wang, MD, Beijing Chao Yang Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024-DM-Lp
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.